The Cutting Edge of Medical Technology Content, Community & Collaboration
OnBioVC Quarterly Bioscience Venture Capital Analysis
Colleagues,
As is always the case, our friends at OnBioVC have done an excellent job of collecting and analyzing venture capital investment in medical devices, biopharmaceuticals, therapeutics, diagnostics, and biofuels for Summer 2009...
Highlights:
- OnBioVC tracked a quarter-over-quarter decline in the number of private biopharma financings as well as a reduction on total capital raised.
- In aggregate 267 Biopharma, Diagnostic, Medical Device and Biofuel venture financings have been completed Year To Date totaling $4.807 billion.
- The Medical Device sector is gaining strength increasing in both the number of deals completed (21 in 3Q08 v. 43 in 3Q09) as well as total capital raised ($445.1M in 3Q08 v. $758.9M in 3Q09).
- In contrast, the Diagnostic sector was flat (8 deals in 3Q08 and 3Q09), and the total capital raised fell by over $50M ($151.1M in 3Q08 v. $98.6M in 3Q09)
- Biopharma venture financings fell (51 in 3Q08 v. 43 in 3Q09), as did total capital raised ($1,087 Billion in 3Q08 v. $755.7M in 3Q09).
- Nearly one-third of all biopharma venture deals closed in 3Q09 were in the oncology space
- The West region continues its dominance in attracting bioscience capital investment. With California serving as home to two centers of bioscience innovation ... in the north in the Bay Area and in the south in San Diego, as well as home to private equity fund concentrations in Silicon Valley and in the Gaslamp, San Diego (there is something to be said for investors being able to attend a Board of Director meeting less than an hour from home).
- A similar cluster exists in the Boston/Cambridge area where there is an overlap of people, IP and money. Consequently, the North East and West continue to lead in number of deals and total capital attracted.
- Initial Public Offerings (IPO): ... Commercial stage entities that are revenue generating seem to be well positioned for a public offerings or acquisitions going forward. Biopharmaceuticals with clinical programs deep into Phase III, submitted INDs, and possible PDUFA dates appear most attractive. The general sentiment offered by OnBioVC is that investors will not reward firms who are far from market at this time.
-- Merger & Acquisition (M&A): In 3Q09 11 M&A deals were struck ... totaling nearly $28B ...
For those interested in greater detail, see the full Trend Analysis attached below...
ENJOY!
CC
As is always the case, our friends at OnBioVC have done an excellent job of collecting and analyzing venture capital investment in medical devices, biopharmaceuticals, therapeutics, diagnostics, and biofuels for Summer 2009...
Highlights:
- OnBioVC tracked a quarter-over-quarter decline in the number of private biopharma financings as well as a reduction on total capital raised.
- In aggregate 267 Biopharma, Diagnostic, Medical Device and Biofuel venture financings have been completed Year To Date totaling $4.807 billion.
- The Medical Device sector is gaining strength increasing in both the number of deals completed (21 in 3Q08 v. 43 in 3Q09) as well as total capital raised ($445.1M in 3Q08 v. $758.9M in 3Q09).
- In contrast, the Diagnostic sector was flat (8 deals in 3Q08 and 3Q09), and the total capital raised fell by over $50M ($151.1M in 3Q08 v. $98.6M in 3Q09)
- Biopharma venture financings fell (51 in 3Q08 v. 43 in 3Q09), as did total capital raised ($1,087 Billion in 3Q08 v. $755.7M in 3Q09).
- Nearly one-third of all biopharma venture deals closed in 3Q09 were in the oncology space
- The West region continues its dominance in attracting bioscience capital investment. With California serving as home to two centers of bioscience innovation ... in the north in the Bay Area and in the south in San Diego, as well as home to private equity fund concentrations in Silicon Valley and in the Gaslamp, San Diego (there is something to be said for investors being able to attend a Board of Director meeting less than an hour from home).
- A similar cluster exists in the Boston/Cambridge area where there is an overlap of people, IP and money. Consequently, the North East and West continue to lead in number of deals and total capital attracted.
- Initial Public Offerings (IPO): ... Commercial stage entities that are revenue generating seem to be well positioned for a public offerings or acquisitions going forward. Biopharmaceuticals with clinical programs deep into Phase III, submitted INDs, and possible PDUFA dates appear most attractive. The general sentiment offered by OnBioVC is that investors will not reward firms who are far from market at this time.
-- Merger & Acquisition (M&A): In 3Q09 11 M&A deals were struck ... totaling nearly $28B ...
For those interested in greater detail, see the full Trend Analysis attached below...
ENJOY!
CC
Views: 6
- Attachments:
-
-
onbiovc-trend-analysis-3q091.pdf, 447 KB
-
MedTechIQ VideoLibrary
Upcoming Events
© 2024 Created by CC-Conrad Clyburn-MedForeSight.
Powered by
